Gregory Renza
Stock Analyst at Truist Securities
(3.46)
# 911
Out of 5,147 analysts
255
Total ratings
42.45%
Success rate
6.42%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Buy | $400 → $412 | $316.99 | +29.97% | 4 | Feb 27, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $145 → $152 | $148.95 | +2.05% | 3 | Feb 11, 2026 | |
| CGON CG Oncology | Maintains: Buy | $66 → $75 | $58.80 | +27.55% | 6 | Feb 10, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $820 → $818 | $781.67 | +4.65% | 3 | Feb 2, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $41 → $40 | $29.38 | +36.15% | 13 | Jan 8, 2026 | |
| AMGN Amgen | Maintains: Hold | $318 → $319 | $388.16 | -17.82% | 19 | Jan 8, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $59 → $60 | $32.20 | +86.34% | 14 | Jan 6, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $38 | $30.23 | +25.70% | 8 | Dec 24, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Buy | $14 → $18 | $8.38 | +114.80% | 5 | Dec 11, 2025 | |
| CATX Perspective Therapeutics | Assumes: Buy | $8 → $12 | $5.40 | +122.22% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $30 | $15.97 | +87.85% | 12 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $12.77 | +127.09% | 10 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.91 | +86.13% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $101.95 | +37.32% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $3.28 | +174.39% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $10 | $5.73 | +74.52% | 4 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $24.75 | +106.05% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $121.28 | +15.44% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $45 → $50 | $44.06 | +13.48% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $24.56 | +5.86% | 16 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $4.10 | +95.12% | 12 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $5 | $1.81 | +176.24% | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $182 → $172 | $190.02 | -9.48% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $113 → $38 | $54.94 | -31.74% | 14 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $7.13 | +68.30% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $5.72 | +144.76% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $21.91 | -17.85% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $1.38 | +3,378.26% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $5.47 | +265.63% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $0.96 | +1,567.01% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $17.50 | +928.57% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $0.92 | +8,626.96% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.26 | +11,242.16% | 3 | Jun 2, 2020 |
BeOne Medicines AG
Feb 27, 2026
Maintains: Buy
Price Target: $400 → $412
Current: $316.99
Upside: +29.97%
Gilead Sciences
Feb 11, 2026
Maintains: Buy
Price Target: $145 → $152
Current: $148.95
Upside: +2.05%
CG Oncology
Feb 10, 2026
Maintains: Buy
Price Target: $66 → $75
Current: $58.80
Upside: +27.55%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Buy
Price Target: $820 → $818
Current: $781.67
Upside: +4.65%
Viridian Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $41 → $40
Current: $29.38
Upside: +36.15%
Amgen
Jan 8, 2026
Maintains: Hold
Price Target: $318 → $319
Current: $388.16
Upside: -17.82%
IDEAYA Biosciences
Jan 6, 2026
Maintains: Buy
Price Target: $59 → $60
Current: $32.20
Upside: +86.34%
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $30.23
Upside: +25.70%
Fulcrum Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $14 → $18
Current: $8.38
Upside: +114.80%
Perspective Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $8 → $12
Current: $5.40
Upside: +122.22%
Nov 24, 2025
Assumes: Buy
Price Target: $23 → $30
Current: $15.97
Upside: +87.85%
Nov 24, 2025
Initiates: Buy
Price Target: $29
Current: $12.77
Upside: +127.09%
Nov 24, 2025
Initiates: Buy
Price Target: $11
Current: $5.91
Upside: +86.13%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $101.95
Upside: +37.32%
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $3.28
Upside: +174.39%
Nov 24, 2025
Initiates: Hold
Price Target: $10
Current: $5.73
Upside: +74.52%
Nov 24, 2025
Initiates: Buy
Price Target: $51
Current: $24.75
Upside: +106.05%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $121.28
Upside: +15.44%
Jul 8, 2025
Downgrades: Sector Perform
Price Target: $45 → $50
Current: $44.06
Upside: +13.48%
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $24.56
Upside: +5.86%
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $4.10
Upside: +95.12%
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $1.81
Upside: +176.24%
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $190.02
Upside: -9.48%
Apr 16, 2025
Maintains: Sector Perform
Price Target: $113 → $38
Current: $54.94
Upside: -31.74%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $7.13
Upside: +68.30%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $5.72
Upside: +144.76%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $21.91
Upside: -17.85%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $1.38
Upside: +3,378.26%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $5.47
Upside: +265.63%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $0.96
Upside: +1,567.01%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $17.50
Upside: +928.57%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $0.92
Upside: +8,626.96%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.26
Upside: +11,242.16%